EDGAR·FLOW

iBio, Inc. — Form 8-K

Filed November 20, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 92/100
What the filing says
On November 19, 2026, iBio, Inc. received notice of delisting or failure to satisfy a continued listing rule or standard, with a potential transfer of listing. The filing does not specify which exchange, the exact rule violated, cure period, or remedial actions. No dollar amounts, timelines, or specific regulatory details are disclosed.
Why this rating

Delisting is existential threat to small-cap biotech; eliminates retail access, credibility, and future financing ability relative to $57.5M market cap.

Extracted items
Price action (we called it negative)
before filing · preread
$0.76
at our read
pending
+10 min
pending
+30 min
pending
+1 hr
pending
+4 hrs
pending

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ IBIO · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.